Nadir Ali: Benefits of LDL reduction are commonly overstated by drug trials

Dr Ali, in his HVMN podcast interview with Geoffrey Woo, explains how drug trials, run by the drug companies themselves have two main problems. One, they have a serious conflict of interest and focus on surrogate markers, like LDL levels, instead of real health outcomes. Two, they use questionable tactics, such as relative risk reduction, in reporting benefits of their intervention.
Original Youtube link: https://youtu.be/zul-maTs--c